Coraliotech

Belkins
Coraliotech is a marine biotechnology company founded in 2018 and based in Monaco. Our activity is dedicated to the discovery, the production and the valorisation of promising marine molecules from coral organisms. Compared to many other species, the corals are still under-studied organisms and should represent a prodigious source of active natural substances with potential applications in the fields of human well-being and health. Unfortunately, since many decades, coral populations are faded and degraded by climate change, pollution and excessive human activities.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

MEDTRONIC EXPANDS MINIMALLY INVASIVE SPINE SURGERY ECOSYSTEM WITH NEXT-GENERATION SPINAL TECHNOLOGIES

Medtronic plc | October 01, 2021

news image

Medtronic plc, the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients. New additions to the Medtronic MIS+ portfolio include: Catalyft™ PL and PL40, the first releases in the new Catalyft™ Expandable Interbody System. Catalyft™ ...

Read More

BIOMARIN EXTENDS GENE THERAPY LEADERSHIP WITH DINAQOR IN A PRECLINICAL COLLABORATION & LICENSE AGREEMENT

BioMarin | May 03, 2020

news image

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform company, to develop novel gene therapies to treat rare genetic cardiomyopathies. DiNAQOR will receive an undisclosed upfront payment and is eligible to receive development, regulatory and commercial milestones on product sales in addition to tiered royalties on worldwide sales. The company did not ...

Read More

DIVERSE BIOTECH ANNOUNCES ORPHAN-DRUG DESIGNATION FOR TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

Diverse Biotech | May 04, 2020

news image

Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, (Orphan Drug Act) including tax credits for qualified clinical te...

Read More

CELL AND GENE THERAPY

DISCOVERY LIFE SCIENCES LAUNCHES GMP COMPLIANT DISCOVERY LEUKOPAKS™ TO ACCELERATE RESEARCH AND DEVELOPMENT OF CELL AND GENE THERAPIES

Discovery Life Sciences | October 28, 2020

news image

Discovery Life Sciences™ (Discovery), a global leader in biospecimen, genomic sequencing, cell, and immunohistochemistry (IHC) services, announces the launch of GMP-compliant Discovery Leukopaks™ and other cell-based products for use in human cell and gene therapy research, development and manufacturing programs. Cell and gene therapies have revolutionized treatment approaches to cancer and other complex diseases. Acceleration of the manufacturing and development of these novel thera...

Read More
news image

MEDTECH

MEDTRONIC EXPANDS MINIMALLY INVASIVE SPINE SURGERY ECOSYSTEM WITH NEXT-GENERATION SPINAL TECHNOLOGIES

Medtronic plc | October 01, 2021

Medtronic plc, the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients. New additions to the Medtronic MIS+ portfolio include: Catalyft™ PL and PL40, the first releases in the new Catalyft™ Expandable Interbody System. Catalyft™ ...

Read More
news image

BIOMARIN EXTENDS GENE THERAPY LEADERSHIP WITH DINAQOR IN A PRECLINICAL COLLABORATION & LICENSE AGREEMENT

BioMarin | May 03, 2020

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform company, to develop novel gene therapies to treat rare genetic cardiomyopathies. DiNAQOR will receive an undisclosed upfront payment and is eligible to receive development, regulatory and commercial milestones on product sales in addition to tiered royalties on worldwide sales. The company did not ...

Read More
news image

DIVERSE BIOTECH ANNOUNCES ORPHAN-DRUG DESIGNATION FOR TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

Diverse Biotech | May 04, 2020

Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, (Orphan Drug Act) including tax credits for qualified clinical te...

Read More
news image

CELL AND GENE THERAPY

DISCOVERY LIFE SCIENCES LAUNCHES GMP COMPLIANT DISCOVERY LEUKOPAKS™ TO ACCELERATE RESEARCH AND DEVELOPMENT OF CELL AND GENE THERAPIES

Discovery Life Sciences | October 28, 2020

Discovery Life Sciences™ (Discovery), a global leader in biospecimen, genomic sequencing, cell, and immunohistochemistry (IHC) services, announces the launch of GMP-compliant Discovery Leukopaks™ and other cell-based products for use in human cell and gene therapy research, development and manufacturing programs. Cell and gene therapies have revolutionized treatment approaches to cancer and other complex diseases. Acceleration of the manufacturing and development of these novel thera...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us